Abstract 832P
Background
MALT1 plays a key role in antigen receptor signalling and preclinical data indicate that MALT1 protease inhibition may have benefit in tumours with dysregulated NF-κB signalling, including activated B-cell-diffuse large B-cell lymphoma (ABC-DLBCL). MALT1 inhibitors are in clinical development as monotherapies and in combination with other agnets for the treatment of oncology and haematology indications, including lymphoma.
Methods
EXS73565 (‘565) was designed using generative design, machine learning and molecular dynamics approaches. The compound was characterised in MALT1 protease assays and DLBCL functional studies. In vivo efficacy of ‘565 was assessed in mouse xenograft models, alone and in combination with the BTK inhibitor ibrutinib. Profiling of ‘565 was undertaken in a range of selectivity and preclinical studies.
Results
‘565 is a potent and selective allosteric inhibitor of the MALT1 protease and inhibits the production of IL-10 and proliferation of DLBCL cells. In ABC-DLBCL xenograft studies, ‘565 demonstrated significant tumour growth inhibition. Tumour target engagement was demonstrated through measurement of the MALT1 protease target, RelB, and effects on NF-κB target genes. In an ABC-DLBCL xenograft model with low sensitivity to single-agent MALT1 and BTK inhibition in vivo, combining ‘565 and ibrutinib provided significant synergistic efficacy. Evaluation of ‘565 showed limited activity against CYP450 enzymes, hepatic and renal transporters. Notably, ‘565 avoids inhibition of UGT1A1 (an enzyme involved in metabolising bilirubin and certain small molecule drugs) in comparison to some clinical stage MALT1 inhibitors which carry a high UGT1A1 inhibition risk.
Conclusions
We describe the characterisation of EXS73565, an allosteric inhibitor of MALT1 which is currently in IND/CTA-enabling studies. Importantly, we show that ‘565 exhibits a low drug-drug interaction and hyperbilirubinemia risk, offering the prospect of fully exploring the potential of MALT1 inhibition as a monotherapy and/or in combination with other targeted agents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Exscientia.
Disclosure
M. Gooyit, S. Varzandeh, A. Gavard, S. Robinson, F. Breitgoff, A. Cooke, A. Bradley, M. Dominguez: Financial Interests, Personal, Stocks/Shares: Exscientia; Other, Personal, Full or part-time Employment: Exscientia. A. Payne: Financial Interests, Personal, Stocks/Shares: Exscientia; Non-Financial Interests, Personal, Full or part-time Employment: Exscientia. C. Carvalheda, D. Evans, S. Richards, P. Ray: Other, Personal, Full or part-time Employment: Exscientia. C. Radoux, J. Besnard: Other, Personal, Full or part-time Employment: Exscientia; Financial Interests, Personal, Stocks/Shares: Exscientia.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18